Skip to main content
Signal8

ALTERITY THERAPEUTICS LTD (ATHE) Form 6-K — Oct 30, 2026

$ATHEForm 6-KFiled Oct 30, 2026, 6:00 AM ET0001437749-26-034060Original filing

Alterity Therapeutics reported that FDA End-of-Phase 2 meeting minutes confirmed agreement on the Phase 3 trial design and registrational pathway for ATH434 in Multiple System Atrophy, including a single pivotal trial with the Phase 2 ATH434-201 data serving as confirmatory evidence. Phase 3 operational start-up activities are underway with roughly 200 patients to be randomized 1:1 to ATH434 50 mg or placebo. The company also received a new U.S. composition of matter patent for ATH434 extending protection to 2045, and new analyses showed ATH434 50 mg slowed functional decline in MSA by approximately 52% versus placebo at Week 52 using methods planned for Phase 3.

Key figures

Cash Position
A$41.3 million
Rd tax refund
A$3,982,992
Phase2 efficacy
ATH434 50 mg slowed functional decline ~52% vs placebo on 11-item UMSARS at Week 52
Option exercise proceeds
approximately A$5.5 million net
Phase3 enrollment target
approximately 200 patients
Estimated quarters funding
30.8
Operating cash outflow qtr
A$1.34 million
Related party payments qtr
A$323k

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.